The Food and Drug Administration is questioning if tobramycin actually does help patients with cystic fibrosis to breathe better. The powdered version of the drug is an alternative to the nebulized version that is called Tobi. The FDA is only questioning the powdered form of the medication. A company called Novartis makes a drug called Tobi. It is a nebulized version of tobramycin. A nebulizer is an electric, or battery-powered machine that turns liquid medication into a fine mist that an adult or child can inhale into their lungs. Some nebulizers have a mouthpiece, and others have a face mask. … Continue reading →

The Food and Drug Administration has approved of the use of a drug called Afinitor Disperz. The FDA has approved it specifically for the use of treating brain tumors in young children who have a rare genetic disease. The drug was cleared under the FDA’s accelerated approval program. Earlier this year, the Food and Drug Administration (FDA) approved a drug called Kalydeco. That was the first drug that the FDA has approved that was designed to help treat the cause of cystic fibrosis. Kalydeco was specifically approved for people who have cystic fibrosis and who are age six or older. … Continue reading →

The Food and Drug Administration has approved a drug called Kalydeco. This is the first drug that has been approved in the United States to treat the cause of cystic fibrosis (in some patients). Kalydeco is extremely expensive. Despite the cost, it holds hope for parents of children who have cystic fibrosis. Cystic fibrosis (CF) is a genetically heritable disease. It occurs when a child receives two abnormal copies of a specific gene. In other words, the child ended up with one abnormal copy of the gene from his mother, and also received one abnormal copy of the gene from … Continue reading →